US-based medical technology firm Innova Medical Group and biochemical testing firm Attomarker have signed a strategic partnership to accelerate immunity testing for Covid and other diseases globally.
Attomarker’s CE-marked and UK Medicines and Healthcare Products Regulatory Agency (MHRA) accredited rapid Covid Antibody Immunity Test will allow patients and health officials to better plan vaccine shots and other preventative measures.
The device, which is already accessible in clinics in the UK and the Caribbean, is the first of its kind to measure an individual’s immune response to a Covid-19 vaccine, booster, and infection.
The immune testing technology measures multiple biomarkers for liver health, food allergies, and fertility in blood and saliva of 20 tests in seven minutes.
Under the partnership, Innova Medical will make a minority investment in Attomarker and will become an official distributor of its products.
Innova’s commercial capabilities in the rapid test area will aid in the development of Attomarker’s multiplexed platform technology, allowing for rapid point-of-care diagnostics and customised medicine advancements.
Innova Medical Group CEO Daniel Elliott said: “We are excited about working with the Attomarker team to help them accelerate growth.
“Adding a much-needed immunity test into Innova’s Covid rapid test portfolio strengthens the pandemic management solution we offer to our global customers.”
Innova chief medical officer Todd Malan said: “Attomarker’s technology has the potential to change healthcare diagnosis and treatment with a portfolio of near-patient rapid diagnostics that would lead to more effective clinical intervention.
“Most immediately, as protection from previous Covid infections and vaccinations decline and boosters continue to roll out, Attomarker’s science-based Covid-19 Antibody Immunity Test will be a valuable tool for individuals to make science-based personalised healthcare decisions.”
Attomarker CEO and founder Andrew Shaw said: “This strategic alliance with Innova delivers a big boost to the Attomarker vision to a truly global perspective.
“We look forward to bringing more rapid solutions to help clinicians optimise interventions and enable people to take greater control over their own health.”
